Damora Therapeutics, Inc. (DMRA) stock

DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30

$21.60−0.45 (-2.04%)

Close on Nov 13, 2026Market cap $1.34BP/E 5.4Yield 0.00%

Damora Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Damora Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?